DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI trimmed its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 19.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,105 shares of the medical device company's stock after selling 3,585 shares during the period. Arcadia Investment Management Corp MI's holdings in DexCom were worth $1,032,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Larson Financial Group LLC lifted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the last quarter. Nia Impact Advisors LLC raised its position in DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after purchasing an additional 140 shares in the last quarter. Level Four Advisory Services LLC raised its position in DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares in the last quarter. Covestor Ltd raised its position in DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its position in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DXCM. Truist Financial began coverage on DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target for the company. Robert W. Baird reduced their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Wall Street Zen downgraded DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Mizuho initiated coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Finally, Barclays boosted their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Five investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Price Performance

NASDAQ DXCM traded up $1.11 during trading hours on Wednesday, reaching $84.87. The company's stock had a trading volume of 2,692,571 shares, compared to its average volume of 4,405,412. The firm has a market capitalization of $33.28 billion, a price-to-earnings ratio of 63.34, a P/E/G ratio of 1.77 and a beta of 1.44. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The company's 50-day moving average is $83.74 and its two-hundred day moving average is $79.90.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company posted $0.32 EPS. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at $7,874,445.60. This trade represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock valued at $2,281,732 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.